Clinical Edge Journal Scan

Pembrolizumab+chemotherapy improves OS in a subgroup of patients with advanced TNBC


 

Key clinical point: First-line treatment with pembrolizumab and chemotherapy improved overall survival (OS) compared with chemotherapy alone in patients with advanced triple-negative breast cancer (TNBC) whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of ≥10.

Major finding: Pembrolizumab+chemotherapy vs placebo+chemotherapy improved OS in patients whose tumors expressed PD-L1 with a CPS of ≥10 (hazard ratio for death 0.73; P = .0185); however, no survival benefits were observed in patients with PD-L1 CPS of ≥1 ( P = .1125). Grade ≥3 adverse events were reported by 68.1% and 66.9% of patients in the pembrolizumab+chemotherapy and placebo+chemotherapy groups, respectively.

Study details : Findings are from an interim analysis of the phase 3 KEYNOTE-355 trial including 847 patients with locally recurrent inoperable or metastatic TNBC who were randomly assigned to receive pembrolizumab+chemotherapy or placebo+chemotherapy.

Disclosures: This study was funded by Merck Sharp and Dohme. Four authors declared being employees of or owning stocks in Merck, and the other authors reported ties with several sources, including Merck.

Source: Cortes J et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217-226 (Jul 21). Doi: 10.1056/NEJMoa2202809

Recommended Reading

Life and death decisions: What keeps oncologists up at night
MDedge Hematology and Oncology
Commentary: Looking at Therapies for Patients With HER2-low Breast Cancer, August 2022
MDedge Hematology and Oncology
Node-negative triple-negative breast cancer prognosis lies within stromal lymphocytes
MDedge Hematology and Oncology
FDA approves trastuzumab-deruxtecan for HER2-low breast cancer
MDedge Hematology and Oncology
Genomic Assays in HR-Positive/HER2-Negative Breast Cancer
MDedge Hematology and Oncology
Genetic counseling for cancer often costs patients nothing
MDedge Hematology and Oncology
Getting cancer research on track again may require a ‘behemoth’ effort
MDedge Hematology and Oncology
Does PREDICT accurately estimate breast cancer survival?
MDedge Hematology and Oncology
The ‘great dynamism’ of radiation oncology
MDedge Hematology and Oncology
Lung adverse effects in patients taking trastuzumab deruxtecan
MDedge Hematology and Oncology